Compare Davita Inc (DVA) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.33. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | VWO | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | — |
52-Week High | $240.96 | $61.24 |
52-Week Low | $103.87 | $51.20 |
Enterprise Value | $24.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
VWO trades at $60.47, up 0.85% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF offers low-cost exposure to emerging markets with a 0.06% expense ratio and a 2.4% dividend yield, attracting institutional inflows as seen in recent SEC filings. Recent news highlights strong investor interest in emerging markets ex-China and AI-driven growth in regions like Taiwan and Thailand.
Outlook is positive due to record capital flows into emerging markets and diversification benefits, but risks include China's economic volatility and currency fluctuations. The ETF's low fees and focus on high-growth economies support long-term potential, though short-term technical indicators suggest caution near resistance at $61.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
